Rise in prevalence of lung cancer and increase
in tobacco smoking across the globe. According to American Cancer Society in
U.S. approximately 195,000 people are suffering from NSCLC every year and the
mortality rate accounts for approximately 135,000. Innovative targeted drug
delivery is also expected to fuel the Lung Cancer Therapeutic
Market growth.
However, limited treatment options, increased
demand for diagnosis, and availability of large number of generic forms of
drugs impede the growth of the global lung cancer therapeutic market.
Asia-Pacific provides growth opportunities for the market due to high incidence
of lung cancer, aging population, and growth in healthcare awareness during the
forecast period.
Download PDF Report
Sample with statistical info @ https://www.alliedmarketresearch.com/request-toc-and-sample/4253
Cancer is a chronic disease that involves the
abnormal growth of cells inside the body, which further results in the
formation of tumor. If untreated, the tumor grows, and hampers the ability of
the lungs to provide oxygen to the blood stream. Lung cancer is the malignant tumor
and is the second most diagnosed cancer that has the highest mortality rate in
both men and women.
The lung cancer is primarily classified into
non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). SCLC is a
critical medical condition as compared to NSCLC due to its size and lack of
availability of drug treatment. Some of the symptoms of lung cancer include
coughing, shortness of breath, weight loss, chest pain and others.
Chemotherapy, radiation therapy, and others are used in the treatment of lung
cancer.
The companies profiled in this report include
Astrazeneca plc, Eli Lilly and Company, GlaxoSmitKline plc, F Hoffman-La Roche
Ltd., Boehringer Ingelheim GmbH, Pfizer Inc., Sanofi-Aventis, ArQule Inc.,
Daiichi Sankyo Co. Ltd, and Agennix AG.
The global lung cancer therapeutic market is
segmented into chemotherapy, radiotherapy targeted therapies, pipeline drugs,
and geography. By chemotherapy, the market is divided into navelbine, hycamtin,
taxotere, alimta, and gemzar. Based on radiotherapy, the market is categorized
into external beam, internal, and systemic. The market based on targeted
therapies is divided intoavastin, abraxane, docetaxel, gefitnib, tarceva,
xalkori, afatinib, dacomitinib, talactoferrin, and iressa. By geography, it is
analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits :
- The study provides an in-depth analysis of
the market with current trends and future estimations to elucidate the
imminent investment pockets.
- It offers a quantitative analysis from 2017
to 2023, which is expected to enable the stakeholders to capitalize on
prevailing market opportunities.
- Comprehensive analysis of all geographical
regions is provided, which helps to determine the prevailing
opportunities.
- Key players are profiled and their
strategies are analyzed thoroughly, which helps understand the competitive
outlook of the market.
- Extensive analysis elucidates the use of
lung cancer therapeutics for the quality treatment of lung cancer.
No comments:
Post a Comment